Practical Applications of Immunology: Vaccines and Diagnostic Immunology

Practical Applications of Immunology

Introduction

This chapter explores the principles and applications of immunology in the prevention, diagnosis, and treatment of infectious diseases. It focuses on vaccines, their types, production, and safety, as well as immunologic diagnostic techniques essential for clinical microbiology.

Vaccines: Principles and Applications

Historical Background and Definitions

• Variolation: An early method of smallpox prevention involving inoculation with material from smallpox scabs (practiced in China, 1400s–1700s).

• Vaccination: Introduced by Edward Jenner (1798) using cowpox material to prevent smallpox; term coined by Pasteur (from vacca, meaning cow).

• Vaccine: A suspension of organisms or their fractions that induce immunity.

Principles and Effects of Vaccination

• Provokes a primary immune response, leading to antibody and memory cell formation.

• Enables a rapid, intense secondary response upon re-exposure.

• Herd immunity: When most of the population is immune, outbreaks are sporadic due to a lack of susceptible hosts.

CDC-Recommended Vaccines

Vaccines are recommended for the prevention of both bacterial and viral diseases. The following tables summarize key vaccines, their recommendations, and booster requirements.

Table: CDC-Recommended Vaccines to Prevent Bacterial Diseases

Disease(s)	Vaccine	Recommendation	Booster
H. influenzae type b meningitis	Polysaccharide from H. influenzae type b	Children 2–18 months	None
Meningococcal ACWY meningitis	Purified polysaccharide from Neisseria meningitidis	Age 11–12 years	At 16 years; outbreak settings
Pneumococcal pneumonia	Polysaccharide from Streptococcus pneumoniae	Adults with chronic diseases, >65 years; children 2–18 months	None if first dose ≥24 months
Tetanus, diphtheria, pertussis	DTaP, Tdap, Td	Children 2–18 months, 4–6 years; Tdap for 11–12 years and adults	Tdap or Td every 10 years

Table: CDC-Recommended Vaccines to Prevent Viral Diseases

Disease(s)	Vaccine	Recommendation	Booster
Chickenpox (varicella)	Attenuated virus	Infants 12 months	Unknown
COVID-19	mRNA	Two-dose series, ages vary	Recommended
Hepatitis B	Virus antigen in yeast cells	Infants, children, high-risk adults	At least 7 years; boosters uncertain
Influenza	Inactivated/attenuated virus	Everyone >6 months	Annual
Measles, Mumps, Rubella	Attenuated virus	Infants 15 months; adults if exposed	During outbreaks

Types of Vaccines and Their Characteristics

• Attenuated vaccines: Weakened pathogens; mimic natural infection; confer lifelong immunity but not for immunocompromised patients due to risk of reversion to virulence.

• Inactivated vaccines: Killed microbes; safer but require boosters; induce mainly humoral immunity.

• Subunit vaccines: Use antigenic fragments; includes recombinant, toxoid, and virus-like particle (VLP) vaccines.

• Polysaccharide vaccines: Made from capsule molecules; not very immunogenic.

• Conjugated vaccines: Polysaccharide linked to protein; effective in young children.

• DNA vaccines: Injected DNA encodes antigen; stimulates humoral and cellular immunity.

• mRNA vaccines: mRNA in lipid nanoparticles encodes antigen; e.g., COVID-19 vaccines.

• Recombinant vector vaccines: Avirulent microbes deliver DNA coding for antigens.

Vaccine Production, Administration, and Safety

• Production: DNA, mRNA, and recombinant vector vaccines do not require animal hosts; plants are being explored as production systems.

• Adjuvants: Substances like alum and monophosphoryl lipid A enhance vaccine effectiveness by stimulating innate immunity.

• Administration: Oral (rotavirus, cholera), nasal (influenza), skin patch, and combination vaccines are used for ease and effectiveness.

• Safety: Vaccines are generally safe; rare cases of disease from live vaccines. No evidence links MMR vaccines to autism. mRNA vaccines have an excellent safety record.

Diagnostic Immunology

Principles of Immunologic Diagnostic Tests

• Sensitivity: Probability that a test detects a true positive.

• Specificity: Probability that a test correctly identifies a true negative.

• Tests are based on antigen-antibody interactions; known antibodies can identify unknown pathogens and vice versa.

Monoclonal Antibodies (Mabs)

• Produced by hybridomas (fusion of myeloma and antibody-producing B cells).

• Uniform, highly specific, and produced in large quantities.

• Applications: diagnostics, therapy (e.g., cancer, autoimmune diseases, COVID-19).

• Types: chimeric, humanized, and fully human antibodies.

Precipitation Reactions

• Soluble antigens react with IgG or IgM to form visible precipitates (lattices).

• Precipitin reactions occur at optimal antigen-antibody ratios (zone of equivalence).

• Tests: Precipitin ring test, immunodiffusion, immunoelectrophoresis.

Agglutination Reactions

• Particulate antigens bind antibodies to form visible aggregates.

• Direct agglutination: Detects antibodies against large antigens; measures titer.

• Indirect (passive) agglutination: Antigen or antibody is attached to particles (e.g., latex beads).

• Hemagglutination: RBCs agglutinate with antibodies; used in blood typing.

Neutralization Reactions

• Antibodies neutralize toxins or viruses, preventing cell damage or infection.

• Virus neutralization tests detect antibodies by their ability to prevent cytopathic effects.

• Viral hemagglutination inhibition tests are used for virus subtyping.

Complement-Fixation Reactions

• Detects antibodies that do not work with precipitation or agglutination.

• Complement binds to antigen-antibody complexes; used for diagnosing viral, fungal, and rickettsial diseases.

Fluorescent-Antibody Techniques

• Antibodies are labeled with fluorescent dyes and visualized with a fluorescence microscope.

• Direct FA tests: Identify microorganisms in clinical specimens.

• Indirect FA tests: Detect specific antibodies in serum using labeled anti-human antibodies.

• FACS (Fluorescence-Activated Cell Sorter): Sorts and counts cells labeled with fluorescent antibodies (e.g., CD4+ T cells in AIDS).

Enzyme-Linked Immunosorbent Assay (ELISA)

• Direct ELISA: Detects antigens using enzyme-linked antibodies and a colorimetric substrate.

• Indirect ELISA: Detects antibodies using antigen-coated wells and enzyme-linked anti-human antibodies.

Western Blotting (Immunoblotting)

• Proteins are separated by electrophoresis, transferred to a membrane, and detected with enzyme-linked antibodies.

• Used for confirming the presence of specific proteins or antibodies (e.g., HIV diagnosis).

Rapid Antigen Tests

• Example: SARS-CoV-2 rapid antigen (lateral flow) test.

• Sample flows through a strip; antigens are captured by labeled antibodies, forming a visible line if positive.

The Future of Diagnostic and Therapeutic Immunology

• Automation and simplification of tests for global accessibility.

• Rapid tests for foodborne pathogens and emerging diseases.

• Monoclonal antibodies as therapeutic agents.

Big Picture: Vaccine-Preventable Diseases

• Immunization campaigns have drastically reduced diseases like diphtheria (from 15,000 deaths in 1921 to 14 cases since 1996 in the US).

• Challenges remain due to poverty, infrastructure, booster requirements, and vaccine hesitancy.

• Global initiatives aim to eliminate diseases such as measles, rubella, and polio.